Skip to content

Psychedelic-assisted therapy: all studies

Page 23 of 294: studies 221 to 230 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Plant-based theatre: Drama therapy assists psychedelic-assisted therapy

Drama Therapy Review April 1, 2025 Brett Alters 1 citation

Psychedelics are naturally derived from plants, fungi and bacteria and their experiential therapeutic use evidences improved environmental appreciation. Drama therapy also builds insight through action-oriented treatment interventions that cultivate empathy. This theoretical article proposes possible benefits in pairing drama therapy with psychedelic-assisted therapy to enhance outcomes due to...

Mitigating Ethical Issues in Training for Psychedelic Therapy

Neuroethics April 1, 2025 Christopher Poppe, Daniel Villiger, Dimitris Repantis et al. 9 citations

Abstract In the present paper, we analyze the ethical issues in training for psychedelic therapy and discuss mitigation strategies for these issues. Specifically, after describing models of psychedelic training, we describe four problems of psychedelic training: (1) the imperative for comprehensive training due to vulnerability of participants, (2) psychedelic but not psychotherapeutic...

DOI: 10.1007/s12152-025-09596-3 (opens in new tab) Full text (opens in new tab) Neuropsychology Training meteorology Psychotherapist Medical education +2

Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses.

Australian & New Zealand Journal of Psychiatry April 1, 2025 Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani et al. 16 citations

To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder. Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted...

Ketamine-Assisted Psychotherapy for Treatment of Co-occurring Borderline Personality Disorder and Depression: A Case Study.

Journal of personality disorders April 1, 2025 Albert Yeung, Michael Alpert, David Mischoulon 3 citations

Borderline personality disorder (BPD) is a mental health condition characterized by a pervasive pattern of impulsivity, affective dysregulation, and cognitive-perceptual symptoms. Treatment of BPD remains a significant challenge to mental health clinicians. People who suffer from BPD frequently have comorbid psychiatric disorders, which makes treatment more complex. This case study describes a...

A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.

Journal of Hospice and Palliative Nursing April 1, 2025 Megan Miller, Molly Meyers, Annona Martin et al. 3 citations

Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of...

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude

The Canadian Journal of Psychiatry March 25, 2025 Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al. 1 citation

Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...

DOI: 10.1177/07067437251328316 (opens in new tab) Treatment-resistant depression Depressive disorders Mood disorders Psilocybin-assisted psychotherapy +4

Qualitative analysis of a patient's experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs

Psychiatry Research Case Reports March 24, 2025 Dan Petrovitch, Jacob Spinks, H.J. Yoo et al. 3 citations

Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a...

DOI: 10.1016/j.psycr.2025.100259 (opens in new tab) Ketamine Psychotherapist Substance use Empirical research

The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.

Journal of Psychiatric Research March 14, 2025 Aron Amaev, Jianmeng Song, Yasaman Kambari et al. 8 citations

Illness anxiety (IA) is characterized by worry or fear in response to living with a chronic illness or a preoccupation with having or acquiring a serious disease in conjunction with absent to mild somatic symptomatology. Death anxiety (DA) may underpin IA and is more common in individuals with life-threatening illness. Treatments for DA and IA, such as psychotherapy and antidepressant drugs,...

DOI: 10.1016/j.jpsychires.2025.03.022 (opens in new tab) Innovative therapeutic approach Profound anxieties Existential dread Mental health peace +2

Māori healthcare professionals' perceptions of psychedelic-assisted therapy: a qualitative study.

New Zealand Medical Journal March 14, 2025 Carly Hanna, Eva Morunga, Alesha Wells et al. 2 citations

Psychedelic-assisted therapies are gaining interest as an innovative treatment for problems with mental health and addictions, and there are several clinical trials in this area currently being conducted in Aotearoa New Zealand. However, many stakeholder groups hold concerns about cultural acceptability and safety. While psychedelic substances have a long history overseas in various Indigenous...

DOI: 10.26635/6965.6740 (opens in new tab) Full text (opens in new tab) Indigenous-health Psychedelic-therapy Maori-culture Traditional-medicine +1

Further education in psychedelic-assisted therapy - experiences from Switzerland.

BMC Medical Education March 5, 2025 Helena Aicher, F Müller, Peter Gasser 11 citations

The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anxiety has led to an increasing demand for specialized training. In Switzerland, MDMA, psilocybin, and LSD are applied in the framework of limited medical use as exceptional treatment options since 2014. The Swiss Medical Association for Psychedelic...

DOI: 10.1186/s12909-025-06871-y (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Mental health treatment Limited medical use Personal psychedelic experience +6